TRVI vs. ANIP, DAWN, ADPT, RCUS, CALT, SYRE, SPRY, OCUL, XNCR, and ETNB
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Adaptive Biotechnologies (ADPT), Arcus Biosciences (RCUS), Calliditas Therapeutics AB (publ) (CALT), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Ocular Therapeutix (OCUL), Xencor (XNCR), and 89bio (ETNB). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs.
ANI Pharmaceuticals (NASDAQ:ANIP) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Trevi Therapeutics has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Trevi Therapeutics' return on equity.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ANI Pharmaceuticals currently has a consensus target price of $77.71, indicating a potential upside of 34.13%. Trevi Therapeutics has a consensus target price of $9.31, indicating a potential upside of 102.45%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than ANI Pharmaceuticals.
In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 12 mentions for ANI Pharmaceuticals and 8 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.02 beat ANI Pharmaceuticals' score of 0.49 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
ANI Pharmaceuticals received 339 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. However, 65.52% of users gave Trevi Therapeutics an outperform vote while only 64.39% of users gave ANI Pharmaceuticals an outperform vote.
ANI Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.
ANI Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
Summary
Trevi Therapeutics beats ANI Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 2/21/2025 by MarketBeat.com Staff
